GLP-1 & Metabolic Research Moderate Evidence

Survodutide

GLP-1/Glucagon dual agonist under active phase 2/3 investigation for metabolic and NASH research.

glp-1glucagonnashlivermetabolic

Ask AI About This Compare Compounds

Half-life

5–6 days

SKUs

Evidence

Moderate Evidence

📖 What Is This?

Survodutide is a dual GLP-1 and glucagon receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide which combines GLP-1 and GIP, survodutide pairs GLP-1 with glucagon agonism. The glucagon component is thought to add liver fat reduction and increased energy expenditure to the GLP-1 effects on appetite and insulin. Phase 2 and 3 trials are underway for obesity and MASH (metabolic-associated steatohepatitis).

🔬 What Are Researchers Studying It For?

Obesity and Weight Management

Phase 2 trials showed survodutide produced significant weight loss at 46 weeks, with results competitive with other advanced compounds in development. Phase 3 SYNCHRONIZE trials for obesity are underway.

MASH and Liver Research

The glucagon component of survodutide makes it particularly suited for liver fat reduction — glucagon receptor activation drives fat oxidation in the liver. MASH (metabolic-associated steatohepatitis) involves liver inflammation driven by excess fat, and phase 2 data showed significant reductions in liver fat content and MASH resolution rates.

Metabolic Syndrome Research

Survodutide addresses multiple components of metabolic syndrome simultaneously — weight, liver fat, insulin sensitivity — through its dual mechanism. Research is examining its effects across the spectrum of metabolic disease.

📊 What Does The Research Suggest?

Phase 2 obesity trial showed significant weight reduction at 46 weeks.
Phase 2 MASH trial showed high rates of liver fat reduction and MASH resolution.
Glucagon agonism appears to add liver-specific benefits beyond what GLP-1 alone produces.
Phase 3 trials underway for obesity and MASH.
Not yet FDA-approved.

⚠️ What Should You Know Before Going Deeper?

Survodutide has not completed phase 3 trials. Glucagon receptor activation increases heart rate as a class effect, which requires monitoring. GI side effects are expected to be consistent with the GLP-1 class. Long-term data and safety at phase 3 scale are not yet available.

⚙️ How It Works In The Body

GLP-1 receptor activation reduces appetite and helps manage blood sugar. Glucagon receptor activation normally raises blood sugar (it is the counter-regulatory response to insulin), but when paired with strong GLP-1 activity, the blood sugar raising effect is balanced, and what remains prominent is glucagon's other effects: it strongly stimulates the liver to burn fat rather than store it, and it raises the overall rate of energy expenditure. The combination creates a dual effect — GLP-1 reduces what goes in (appetite) while glucagon increases what gets burned (metabolic rate and fat oxidation). This pairing is thought to be particularly effective for liver fat conditions like MASH.

🛡️ Research Safety Observations

Not FDA-approved. In phase 2 trials, survodutide showed GI side effects consistent with GLP-1 class compounds. Heart rate increases from glucagon receptor activation are documented and require monitoring. MASH trials require careful safety monitoring given the underlying liver disease in participants. Phase 3 safety data are still being collected.

📋 Research Snapshot

Moderate Evidence

This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.

Published Research Ranges

0.6–6mg weekly in phase 2 studies

Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

📄 Research Sources

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Survodutide (BI 456906), a Glucagon and GLP-1 Dual Agonist, in Overweight/Obese Adults: Phase 2 Trial

The Lancet Diabetes & Endocrinology • 2023 • DOI: 10.1016/S2213-8587(23)00263-8

Survodutide

Want More Detailed Research?